Bacterial “immune system” used to engineer human DNA in human cells

Precisely engineering the genome of human cells remains largely in the realm of science fiction. It’s possible, with the right virus, to get new or modified genes into cells. But the regular collection of the genes in the cell are still there—we can’t typically eliminate a gene that has gone bad or replace a broken copy with a working one. Although some progress has been made in creating proteins that target specific spots in the genome, it’s tough to make these proteins both specific enough to only target a single sequence yet flexible enough to work on lots of targets.

Now, it turns out we don’t have to make proteins after all. Bacteria have a system that targets the DNA of viral invaders, acting a bit like an immune system. And two teams of researchers have shown it’s possible to direct that system so it targets specific locations in a mammalian genome. Once targeted, the cell’s normal DNA repair system can replace the sequence with an engineered one of the researchers’ choosing.

The efficiency is under 10 percent, so don’t start thinking we’re going to edit every cell of the human body. But that rate still makes it practical for a variety of purposes—and potentially even therapies.

View the original article here: Bacterial “immune system” used to engineer human DNA in human cells

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT Image May 10, 2026, 08_16_59 PM 2
Overmedicalization? RFK Jr.’s antidepressant crackdown raises conflict questions over his fee stake in Wisner Baum, the tort firm built on suing drug makers
Picture1-5
Science Disinformation Gap: The transatlantic battle over social media and censorship
Screenshot-2026-05-01-at-1.29.41-PM
Viewpoint: What happens when whole grains meet modern food manufacturing? Labels don’t tell the whole story.
S
As vaccine rejectionism spreads, measles may be taking a more dangerous turn
ChatGPT-Image-Apr-13-2026-02_20_22-PM
Viewpoint: Misinformation infodemic? Why assessing evidence is so challenging 
Screenshot-2026-04-20-at-2.26.27-PM
Viewpoint — Food-fear world: The latest activist scientists campaign: Cancer-causing additives
Screenshot-2026-03-13-at-12.14.04-PM
The FDA wants to make many popular prescription drugs OTC—a great idea. Here’s why it’s unlikely to happen
Screenshot-2026-05-08-at-3.40.33-PM
Seeds of power: China turns to genetic engineering to become global superpower
ChatGPT-Image-Mar-27-2026-11_47_30-AM-2
FDA’s expedited drug reviews are hailed in some quarters but other approval practices are problematic
bigstock opioids on chalkboard with rol
GLP podcast: 'Safe injection sites': enabling drug addiction or saving lives?
Picture1-14
When superbugs threaten vulnerable children: Can AI help solve antibiotic resistance?
circular-bioeconomy-should-focus-on-sustainable-wellbeing
GLP podcast: What's wrong with 'doomsday' environmentalism? It's false.
Farmers can talk to plants
Farmers are a major source of misinformation—about farming
Screenshot 2026-05-08 at 3.01
Transforming farming and nutrition with AI and robotics? Larry Ellison’s half-billion-dollar Hawaii greenhouse dream goes bust
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.